You are here: Home » Current Affairs » Coronavirus » News
Business Standard

No Sputnik V approval yet, SEC asks Dr Reddy's for more data on vax

The Subject Expert Committee (SEC) of the Indian drug regulator, tasked with vetting Covid-19 vaccine proposals, sought additional data on Russian Covid-19 vaccine 'Sputnik V'

Topics
Coronavirus Vaccine | Coronavirus | Russia

IANS  |  New Delhi 

Sputnik V, Dr Reddy’s Laboratories, DRL, coronavirus, vaccine, covid-19

The Subject Expert Committee (SEC) of the Indian drug regulator, tasked with vetting Covid-19 vaccine proposals, sought additional data on Russian Covid-19 vaccine 'Sputnik V', while deciding on its emergency use authorisation, a senior government official said on Thursday.

In September 2020, Dr. Reddy's had partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India. The company had conducted Phase 2 trials in India with 1,500 participants. Phase three trials are underway.

The Hyderabad-based pharma major had applied for its emergency licensure on February 19. The Committee looked into Dr. Reddy's application, on Thursday. Sputnik V has not received the emergency use authorisation yet, as the SEC has sought additional data, according to top sources.

In February, the committee had asked the pharma company to furnish immunogenicity data. The approval, if granted, would make Sputnik V the third vaccine to be administered in India.

had registered Sputnik V in August, ahead of large-scale clinical trials, which had raised concerns among many experts over the fast-track process. However, later reviews have shown the vaccine to be both safe and effective in preventing Covid-19.

The efficacy of Sputnik V is 91.6 per cent as confirmed by the data published in the Lancet. The vaccine is based on human adenoviral vectors, which cause common cold. It uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration.

The RDIF had earlier announced four manufacturing deals with Indian pharmaceutical makers -- Virchow Biotech Private Limited, Gland Pharma Private Limited, Stelis Biopharma and Hetero Biopharma.

So far, more than six crore doses of corona vaccine have been administered in the country since the drive began on January 16 after the approval for 'Covishield' and 'Covaxin'.

--IANS

aka/ash

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, April 01 2021. 22:01 IST
RECOMMENDED FOR YOU